Clinical Trial

A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated October 21, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-07-24; most recent amendment 2025-09-11.
Status change: Not Yet Recruiting → Recruiting 2023-08-11
Trial Details
NCT Number NCT05970237
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Diabetes Mellitus, Hypertension
Enrollment 9,000 participants
Start Date 2023-07-26
Primary Completion 2025-10-21 (estimated)
Study Completion 2025-10-21 (estimated)
Updated on ClinicalTrials.gov 2025-09-15